Extended Data Table 2 Clinical observations and chemistry after single and multiple doses of trispecific Ab in NHPs

From: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

  1. Non-human primates treated with a single dose (100, and 100 µg/kg SC) or those treated with repeated doses (30,30,30,30µg/kg IV) were observed for clinical signs of adverse effects (AE). Low grade AE (vomiting and diarrhea) was observed at 100 µg/kg IV, with one animal needing supported care after 24 h. No clinical AE was reported for subcutaneously administrated group (100 µg/kg). Low grade AE (vomiting) was observed at 30 µg/kg multi-dosing for two animals early in the regimen, but not after the last administration.
Back to article page